BioMarin Alesta Therapeutics Acquisition: BioMarin Acquires Alesta to Secure Oral HPP Candidate ALE1 for $275M Upfront
The BioMarin Alesta Therapeutics acquisition secures lead oral asset ALE1 for $275M upfront plus milestones, expanding BioMarin’s rare disease skeletal pipeline.
AstraZeneca Discontinues Volrustomig Phase III Trial in First-Line Metastatic Non-Small Cell Lung Cancer
AstraZeneca has officially stopped its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy in first-line metastatic NSCLC following a recommendation from the Independent Data Monitoring Committee.
Pfizer Valneva Lyme Disease Vaccine Candidate Clears EMA Application Review Milestone
The European Medicines Agency has validated Pfizer and Valneva’s Marketing Authorization Application for PF-07307405, a 6-valent Lyme disease vaccine candidate that showed over 70% efficacy in the Phase 3 VALOR trial.
Bristol Myers Squibb ZENBEXUS Wins FDA Accelerated Approval for Multiple Myeloma
The FDA has granted accelerated approval to Bristol Myers Squibb ZENBEXUS (iberdomide), the first CELMoD therapy ever cleared, paired with daratumumab and dexamethasone for multiple myeloma patients as early as first relapse.
Thermo Fisher Scientific Microbiology Business Sale to Astorg Reaches Completion at $1.075 Billion
Thermo Fisher Scientific has completed the sale of its microbiology business to Astorg for approximately $1.075 billion in cash and a $50 million seller note. The divested unit, part of the Specialty Diagnostics segment, generated $645 million in 2025 revenue from antimicrobial susceptibility testing and culture media solutions.
Eli Lilly Retatrutide Black Market Draws Six New U.S. Lawsuits From Drugmaker
Eli Lilly has filed six new U.S. lawsuits against sellers in the Eli Lilly retatrutide black market, adding to referrals covering more than 200 entities and 14,000 illegal listings. The drugmaker is calling on platforms and payment firms to help shut down the illegal trade.
Novo Nordisk Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes, Now Available Nationwide in the US
Novo Nordisk Awiqli, the first FDA-approved once-weekly basal insulin for type 2 diabetes, has launched nationwide across more than 70,000 US pharmacies, cutting basal injections from seven per week to one.
Charles River Laboratories Q2 2026 Earnings: Revenue Hits $1.00 Billion as Company Raises Full-Year Guidance
Charles River Laboratories (NYSE: CRL) posted Q2 2026 revenue of $1.00 billion and non-GAAP EPS of $3.02, then raised full-year guidance on strengthening DSA demand and Manufacturing outperformance, even as GAAP results absorbed a one-time loss from its CDMO and Cell Solutions divestiture.
Moderna mFLUSIVA FDA Approval: Moderna Receives U.S. FDA Approval for Seasonal Influenza Vaccine mFLUSIVA
The U.S. FDA grants market approval for Moderna’s mFLUSIVA (mRNA-1010) seasonal flu vaccine in adults 50+. Review Phase 3 trial data, efficacy, and rollout details.
Eli Lilly Q2 2026 Earnings Jump 48% as Mounjaro, Zepbound Fuel Growth; Company Raises Full-Year Guidance
Eli Lilly Q2 2026 earnings rose 48% to $23.0 billion, driven by Mounjaro and Zepbound demand, as the company raised full-year revenue and EPS guidance and advanced its obesity, oncology, and immunology pipeline through regulatory wins and four completed acquisitions.